Parameters
Low concentration Cminss<1.0mg/L ( n=31) Standard concentration Cminss=1.0-5.5mg/L (n=55) High concentration Cminss>5.5mg/L (n=30)
P value
Voriconazole Cminss (n)
Demographics
Agea (yr) 56.00(43.00,62.00) 51.91±16.025 54.33±17.810 0.535
Sex
Maleb 26(83.9%) 38(69.1%) 21(70.0%) 0.296
Femaleb 5(16.1%) 17(30.9%) 9(30.0%)
BMIa 22.84±3.727 23.71±3.381 23.12±4.103 0.548
Administration routeb
Intravenous 22(71.0%) 43(78.2%) 25(83.3%) 0.506
Oral 9(29.0%) 12(21.8%) 5(16.7%)
Concomitant medicationsb
PPI 9(29.0%) 14(25.5%) 12(40.0%) 0.372
GC 9(29.0%) 13(23.6%) 4(13.3%) 0.325
Carbapenems 15(48.4%) 29(52.7%) 21(70.0%) 0.187
SMZ/TMP 6(19.4%) 13(23.6%) 5(16.7%) 0.733
Indication for VRCb
Therapy of probable 4(12.9%) 5(9.1%) 5(16.7%) 0.858
Diagnostic-driven therapy of undefined and possible
25(80.6%)
42(76.4%)
21(70.0%)
Empirical antifungal therapy of febrile neutropenia
1(3.2%)
5(9.1%)
3(10.0%)
Prophylaxis 1(3.2%) 3(5.5%) 1(3.3%)
Laboratory parametera
CRP (mg/L) 20.13(7.80,59.00) 31.40(10.40,71.80) 115.35±82.967*** <0.001
PCT (ng/ml) 0.23(0.17,2.00) 0.25(0.16,2.39) 0.34(0.16,6.28) 0.554
Alb (g/L) 34.36±4.069 34.27±4.539 31.85(28.10,33.83)** 0.007
TP (g/L) 66.84±7.174 63.87±8.865 62.95(59.76,67.83) 0.137
ALT (U/L) 30.10±30.486 19.00(12.00,34.00) 16.00(6.75,28.00) 0.264
AST (U/L) 18.00(10.25,30.75) 21.00(13.00,36.00) 24.00(13.75,35.50) 0.296
ALP(U/L) 116.00±65.077 102.00(78.00,151.00) 83.50(68.50,130.00) 0.318
T-BIL (umol/L) 9.00(7.50,11.00) 9.60(6.20,14.10) 11.45(8.80,23.80)* 0.024
SCr (umol/L) 60.00(49.00,77.00) 59.00(53.00,73.00) 67.00(52.50,77.75) 0.631
GFR (ml/(min*1.73m²)) 102.59±31.807 110.10(93.48,120.19) 103.15(95.06,120.78) 0.6